A review of the DTaP-IPV-HB-PRP-T Hexavalent vaccine in pediatric patients
Introduction Hexaxim is a hexavalent vaccine approved as primary and booster vaccination in infants 6 weeks and older, protecting against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae type b. Areas Covered To evaluate the immunogenicity and reactogenicity (saf...
Saved in:
Main Authors: | Andrew Dakin (Author), Ray Borrow (Author), Peter D. Arkwright (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
DTaP5-IPV-Hib-HepB, a hexavalent vaccine for infants and toddlers
by: Andrew W. Lee, et al.
Published: (2017) -
DTaP-IPV-HB-Hib vaccine (Hexaxim): an update 10 years after first licensure
by: Florence Boisnard, et al.
Published: (2023) -
A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)
by: Andrea Guerra, et al.
Published: (2024) -
Acceptance and willingness to pay for DTaP-HBV-IPV-Hib hexavalent vaccine among parents: A cross-sectional survey in China
by: Aodi Huang, et al.
Published: (2024) -
Immunogenicity and safety of a DTaP-IPV//PRP~T combination vaccine given with hepatitis B vaccine: a randomized open-label trial
by: Maria Rosario Capeding, et al.
Published: (2008)